UBX - ユニティ―・バイオテクノロジ― （Unity Biotechnology Inc.） ユニティ―・バイオテクノロジ―UBXのチャート
UBXの企業情報
| symbol | UBx |
|---|---|
| 会社名 | Unity Biotechnology Inc （ユニティ―・バイオテクノロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Unity Biotechnology Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis vision loss and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules UBX0101 and UBX1967 designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins. ユニティ―・バイオテクノロジ―は米国のバイオ医薬品企業。主に、ヒトの健康状態を拡張するための治療法の研究開発に従事する。同社候補薬は関節炎の初期治療に焦点を当てた筋骨格疾患のための「UBX0101」や眼科疾患のための「UBX1967」を含む。また、肺障害治療のためのプログラムを開発する。本社所在地はカリフォルニア州ブリスベン。 UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. |
| 本社所在地 | 3280 Bayshore Blvd. Suite 100 Brisbane CA 94005 USA |
| 代表者氏名 | Keith R. Leonard キース・R・レナード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 415-328-5504 |
| 設立年月日 | 39873 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.unitybiotechnology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ubx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） ー |
| 終値（lastsale） | 13.61 |
| 時価総額（marketcap） | 575903584.18 |
| 時価総額 | 時価総額（百万ドル） 487.04260 |
| 売上高 | 売上高（百万ドル） -- |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 301.07160 |
| 当期純利益 | 当期純利益（百万ドル） -- |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Unity Biotechnology Inc revenues was not reported. Net loss increased 77% to $36.1M. Higher net loss reflects Research and development - Balancing val increase of 60% to $25.3M (expense) Stock-based Compensation in R&D increase from $375K to $2.9M (expense) general increase of 51% to $6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$6.52 to -$5.45. |
UBXのテクニカル分析
UBXのニュース
Unity Biotechnology Inc. (UBX) will benefit from these strategies 2022/11/09 13:08:00 US Post News
Unity Biotechnology Inc. (NASDAQ:UBX) marked $2.46 per share on Tuesday, up from a previous closing price of $2.44. While Unity Biotechnology Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -89.58%, with highs and lows ranging from $36.40 to […]
Unity Biotechnology GAAP EPS of -$1.36 misses by $0.30 2022/11/08 22:49:21 Seeking Alpha
Unity Biotechnology press release (UBX): Q3 GAAP EPS of -$1.36 misses by $0.30.The company believes that current cash, cash equivalents, and marketable securities of $103.9M…
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates 2022/11/08 21:10:00 GlobeNewswire
- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months -
Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors 2022/11/02 15:30:00 Stocks Register
Unity Biotechnology Inc. (NASDAQ:UBX) traded at $2.75 at close of the session on Tuesday, 11/01/22, made a downward move of -3.85% on its previous day’s price. Looking at the stock we see that its previous close was $2.86 and the beta (5Y monthly) reads 0.54 with the day’s price range being $2.67 – $3.74. In … Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors Read More »
Unity Biotechnology (UBX) Stock Pops on Positive Study Data 2022/11/01 16:45:12 InvestorPlace
Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325.
Unity Biotechnology Inc. (UBX) will benefit from these strategies 2022/11/09 13:08:00 US Post News
Unity Biotechnology Inc. (NASDAQ:UBX) marked $2.46 per share on Tuesday, up from a previous closing price of $2.44. While Unity Biotechnology Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -89.58%, with highs and lows ranging from $36.40 to […]
Unity Biotechnology GAAP EPS of -$1.36 misses by $0.30 2022/11/08 22:49:21 Seeking Alpha
Unity Biotechnology press release (UBX): Q3 GAAP EPS of -$1.36 misses by $0.30.The company believes that current cash, cash equivalents, and marketable securities of $103.9M…
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates 2022/11/08 21:10:00 GlobeNewswire
- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months -
Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors 2022/11/02 15:30:00 Stocks Register
Unity Biotechnology Inc. (NASDAQ:UBX) traded at $2.75 at close of the session on Tuesday, 11/01/22, made a downward move of -3.85% on its previous day’s price. Looking at the stock we see that its previous close was $2.86 and the beta (5Y monthly) reads 0.54 with the day’s price range being $2.67 – $3.74. In … Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors Read More »
Unity Biotechnology (UBX) Stock Pops on Positive Study Data 2022/11/01 16:45:12 InvestorPlace
Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325.
Is Unity Biotechnology Inc. (NASDAQ:UBX) A Better Buy Than Others After A -83.60% Fall In This Year? 2022/10/15 15:30:00 Marketing Sentinel
In last trading session, Unity Biotechnology Inc. (NASDAQ:UBX) saw 0.74 million shares changing hands with its beta currently measuring 0.76. Company’s recent per share price level of $0.39 trading at -$0.01 or -3.19% at ring of the bell on the day assigns it a market valuation of $58.24M. That closing price of UBX’s stock is … Is Unity Biotechnology Inc. (NASDAQ:UBX) A Better Buy Than Others After A -83.60% Fall In This Year? Read More »
UNITY Biotechnology''s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye 2022/10/11 12:00:00 Benzinga
- Presentations from UNITY''s leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (NASDAQ: UBX ), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, tomorrow will host an Investor and Analyst Day with presentations highlighting the UBX1325 program, a novel Bcl-xL inhibitor for the treatment of age-related diseases of the eye, followed by a fireside chat with retina expert Robert Bhisitkul, M.D., Ph.D. Presentations include a review of the BEHOLD data in diabetic macular edema (DME), an overview of the recently added long-term extension arms to the Phase 2 ENVISION study in wet age-related macular degeneration (wAMD), as well as clinical development plans, near-term data milestones, and the latest research supporting the therapeutic approach of targeting senescent cells in diseased retinal tissue. "We''re encouraged by the momentum our ophthalmology program has garnered as UBX1325 advances through the clinic and is emerging as a potentially new class of medicine in DME and wAMD," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "Based on the potential efficacy we''ve already seen in patients with DME up to 18 weeks following a single injection of UBX1325 in our ongoing Phase 2 BEHOLD study, we are exploring additional indications where new treatment options are much needed.
UBX vs. AERI: Which Eyecare Stock Has the Most Upside Potential? 2022/10/05 02:18:13 TipRanks
Bearish sentiment continues to have a strong impact on the U.S. stock market, and the healthcare sector has suffered as well, with a year-to-date decline of more than 15%. Some healthcare stocks have performed well while others have not. However, underperforming healthcare stocks could provide interesting investment opportunities. Two stocks to consider in this regard are Unity Biotechnology (NASDAQ: UBX) and Aerie Pharma (NASDAQ: AERI). The former shows high upside potential, while the latter, barring an acquisition by Alcon (NYSE: ALC), isn''t as promising.
Breathtaking stocks: Unity Biotechnology, Inc. (NASDAQ:UBX -0.95%), National CineMedia, Inc. (NASDAQ:NCMI -4.68%) 2022/09/21 00:20:26 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Breathtaking stocks: Unity Biotechnology, Inc. (NASDAQ:UBX -0.95%), National CineMedia, Inc. (NASDAQ:NCMI -4.68%) appeared first on Stocks Equity .
Unity Biotechnology Inc. (UBX) deserves closer scrutiny 2022/09/20 11:16:00 US Post News
A share of Unity Biotechnology Inc. (NASDAQ:UBX) closed at $0.45 per share on Monday, down from $0.47 day before. While Unity Biotechnology Inc. has underperformed by -2.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -85.08%, with highs and lows ranging from $3.64 […]